Circulating microRNAs as Disease Markers in Pediatric Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01541800|
Recruitment Status : Unknown
Verified February 2016 by Rishi Lulla, Ann & Robert H Lurie Children's Hospital of Chicago.
Recruitment status was: Recruiting
First Posted : March 1, 2012
Last Update Posted : February 5, 2016
MicroRNAs are small molecules which have recently been discovered in cells. They are known to be responsible for the normal development of cells and when they are disrupted can contribute to the development of cancer. Many previous studies have been done evaluating the expression of microRNAs in normal tissues as well as a wide variety of cancers.
Recently, microRNAs from tumor cells have been detected circulating in the blood of patients with cancer. This presents a novel opportunity to use microRNAs in the blood as an early predictor of cancer as well as a marker of response to therapy. No previous studies have been performed evaluating microRNAs in the blood or cerebrospinal fluid of patients with childhood cancers. We propose a feasibility study to evaluate the presence of microRNAs in the blood and cerebrospinal fluid of patients with central nervous system tumors, leukemia and lymphoma who are currently on chemotherapy and undergoing blood draws, lumbar punctures and/or reservoir taps for routine clinical care. If we're able to identify circulating microRNAs in this population of pediatric patients, we will build upon this data in proposing a future study.
|Condition or disease|
|Leukemia Lymphoma Central Nervous System|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||July 2018|
All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
- Determine if miRNAs are present in the blood of patients with pediatric cancers [ Time Frame: 1 year ]
- Determine if miRNAs are detectable in the CSF of patients with pediatric cancers. [ Time Frame: 1 year ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01541800
|Contact: Rishi Lulla, MDemail@example.com|
|Contact: Margaret Nevinsfirstname.lastname@example.org|
|United States, Illinois|
|Ann & Robert H. Lurie Children's Hospital of Chicago||Recruiting|
|Chicago, Illinois, United States, 60611|
|Contact: Margaret Nevins 312-227-4861 email@example.com|
|Principal Investigator: Rishi Lulla, MD|
|Principal Investigator:||Rishi Lulla, MD||Ann & Robert H Lurie Children's Hospital of Chicago|